Noncontrolling Interest

6 Months Ended

Jun. 30, 2018

19. Noncontrolling Interest

As of June 30, 2018, a noncontrolling interest of $13,471 was recognized in the Company’s condensed consolidated balance sheet, representing the capital cash contribution by GET in BeiGene Biologics as of June 30, 2018, offset by comprehensive losses attributable to GET’s noncontrolling interest in BeiGene Biologics.

For the three and six months ended June 30, 2018, net losses of $828 and $1,348 attributable to the noncontrolling interest of BeiGene Biologics were recognized in the Company’s condensed consolidated statements of operations, based on GET’s 5% equity interest in BeiGene Biologics.

Reconciliation for the equity attributable to noncontrolling interests for the six months ended June 30, 2018 is as follows:


	BeiGene, Ltd.	Noncontrolling
	Shareholders’ Equity	Interest	Total Equity
	$	$	$
Balance as of January 1, 2018	669,809	14,422	684,231
Net loss	(261,483)	(1,348)	(262,831)
Issuance of ordinary shares in follow-on offering, net of transaction costs	757,587	—	757,587
Share-based compensation	36,037	—	36,037
Exercise of options	10,582	—	10,582
Adjustment to opening balance of equity	(2,666)	375	(2,291)
Other comprehensive income, net of tax of nil:
Foreign currency translation adjustments	2,283	22	2,305
Unrealized holding gain, net	1,048	—	1,048
Other comprehensive income, net of tax of nil	3,331	22	3,353
Balance as of June 30, 2018	1,213,197	13,471	1,226,668